In prostate cancer and breast cancer, EZH2 has been shown to repress the expression of E-cadherin [8] and RUNX3 [9], resulted in promotion of EMT and invasive phenotype and increased cell proliferation, respectively. Here, CDH1 is linked to prostate carcinoma.